A Study on the Safety and Immunogenicity of Combined Intradermal and Intravenous Administration of an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Previously Treated Unresectable Stage III or IV Melanoma

NCT01066390 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
18
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Bart Neyns